|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We thus find a close association between the pattern of PTHrP gene expression and the outcome of breast cancer.
|
10027905 |
1999 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published.
|
23544012 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently identified a unique peptide fragment of parathyroid hormone-related protein (PTHrP), PTHrP(12-48), as a validated serum biomarker in breast cancer patients that correlates with and predicts the presence of bone metastases.
|
28370412 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that PTHrP(38-94) amide restrains growth and invasion in vitro, causes striking toxicity and accelerates death of some breast cancer cell lines, the most responsive being MDA-MB231, for which tumorigenesis was also attenuated in vivo.
|
17516841 |
2007 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously reported that high extracellular Ca2+ stimulates parathyroid hormone-related protein (PTHrP) release from human prostate and breast cancer cell lines as well as from H-500 rat Leydig cancer cells, an action mediated by the calcium-sensing receptor (CaR).
|
15336602 |
2004 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two of these seven SNPs are in linkage disequilibrium (LD) with SNPs associated with breast cancer (those near ESR1 and PTHLH), and a third (ZNF365) is near, but not in LD with, a breast cancer SNP.
|
22747683 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Two of the loci lie in regions that contain strong plausible candidate genes: PTHLH (12p11) has a crucial role in mammary gland development and the establishment of bone metastasis in breast cancer, and NRIP1 (21q21) encodes an ER cofactor and has a role in the regulation of breast cancer cell growth.
|
22267197 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two of the loci lie in regions that contain strong plausible candidate genes: PTHLH (12p11) has a crucial role in mammary gland development and the establishment of bone metastasis in breast cancer, and NRIP1 (21q21) encodes an ER cofactor and has a role in the regulation of breast cancer cell growth.
|
22267197 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transforming growth factor-beta is of particular importance because it increases breast cancer production of PTHrP.
|
14600590 |
2003 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, by controlling the expression of PTHrP and its downstream OPG/RANKL, TF-SB has significant inhibition effects on breast cancer bone metastasis, which indicates a new therapeutic method.
|
29512770 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that transient estrogen- or tamoxifen-induced hypercalcemia in patients with breast carcinoma may be a PTHrP-mediated effect that is a marker of ER positivity.
|
9790998 |
1998 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data support the idea that PTHrP is not predictive of the metastasis of human breast cancer to bone.
|
12359770 |
2002 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The statistical analysis revealed that PTHRP- and KRT19-positive detections correlated with the diagnosis of breast cancer while the combined positive detections of PTHRP-plus-KRT19 correlated with the presence of distant metastasis, especially with bone metastasis.
|
25368276 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of PTHrP in breast cancer growth and metastasis may thus be mediated via upregulation of integrin alpha6beta4 expression and Akt activation, with consequent inactivation of GSK-3.
|
16965770 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The humanized anti-PTHrP mAb was effective against bone metastasis by inducing osteogenesis and, therefore, will provide a new treatment option for bone metastasis in breast cancer.
|
16309168 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The high incidence of PTH-rP production by primary breast carcinomas, elevated plasma levels in 60% of those with hypercalcemia and lytic metastases, and higher incidence of PTH-rP production in skeletal versus those with nonskeletal metastases have led to the hypothesis that PTH-rP might contribute to breast carcinoma growth in bone.
|
9362423 |
1997 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The growth in vitro and in vivo and production of parathyroid hormone-related protein, a key cytokine in the pathogenesis of osteolytic bone metastases in breast cancer, were promoted in MDAsrc527 and diminished in MDAsrc295.
|
12941830 |
2003 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The gene expression signature associated with loss of PTHrP expression in vivo correlated with poorer outcome in human breast cancer.
|
19723659 |
2009 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of these studies was to determine the tissue location of PTHrP/PTH receptors (PTHrPR) in primary breast carcinomas and to establish whether they had the potential to respond to PTHrP.
|
9390035 |
1997 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the regulation of PTHrP and PTHrP-R by breast cancer cells has been poorly investigated so far, we have chosen the 8701-BC cell line as a model system to investigate whether alterations in the extracellular Ca2+ concentration ([Ca2+]e) and treatment with some well-known differentiation agents for breast cells, such as dimethyl sulfoxide, hydrocortisone, progesterone, prolactin, all-trans retinoic acid and transforming growth factor-beta1 might (i) modulate quantitatively the release of iPTHrP, (ii) affect the PTHrP promoter usage and mRNA splicing patterns, and (iii) modify the expression of PTHrP-R.
|
10839458 |
2000 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RNA interference of endogenous PTHrP caused a significant reduction in cell adhesion of a breast cancer cell line to collagen type I, fibronectin and laminin (P<0.05) and of a colon cancer cell to collagen type I and fibronectin (P<0.05).
|
17406357 |
2007 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prolactin stimulated PTHrP transcript and protein in breast cancer cell lines <i>in vitro</i> and <i>in vivo</i>, effects mediated by Stat5 through the P2 gene promoter, producing transcript AT6 encoding the PTHrP 1-173 isoform.
|
30097435 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Paraffin sections of 17 primary and 26 metastatic lesions, 11 of which were in bone, were available for the study: 10 of the 17 (59%) primary lesions, 8 of 11 (73%) breast cancer metastases to bone, and 3 of 15 (20%) metastases to non-bone sites showed specific localization of PTHrP mRNA.
|
1442211 |
1992 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteolysis can be induced by parathyroid hormone-related protein (PTHrP) produced by breast cancer cells that results in an increased osteoblastic RANKL/OPG ratio.
|
16585187 |
2006 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Once formed, Smad2/3:Gli2 complexes stimulate the expression of parathyroid hormone-related protein necessary for breast cancer metastasis to bone.
|
26160166 |
2015 |